glp-1 europe Uptake by Country: Where Ozempic and Mounjaro are Booming in 2026 Europe Glucagon-like Peptide-1 (GLP-1) Agonists

The trial involved 1879 patients with inadequate glycemic control on metformin monotherapy, who were randomly assigned to receive tirzepatide at doses of 5 mg, 10 mg, or 15 mg, or semaglutide at a dose of 1 mg.After 40 weeks of treatment, all doses of tirzepatide were found to be noninferior and superior to semaglutide in terms of reducing glycated hemoglobin (HbA1c) levels

Research shows: Slowed progression of chronic kidney disease (CKD) Reduced proteinuria (albumin in urine) , an early marker of kidney damage Improved kidney filtration rates over time The FLOW trial with semaglutide demonstrated that GLP-1 therapy could significantly reduce the risk of kidney failure in patients with type 2 diabetes and CKD

Link in comments

How ???Safe

Perasaan bahaya yang tiba-tiba